Genzyme Corporation

Ksq Therapeutics, Inc.

Hanlan Liu

Seng H Cheng

Craig S Siegel

John Marshall

Bradford Hirth

John P Leonard

Elyse Bourque

James W Lillie

Abizer I Harianawala

Elina Makino

Giuseppe Lapadula

Diane P Copeland

Paul Mason

Mary A Cromwell

Bing Wang

Thomas O'Shea

Jianmei Kochling

Renu Bhardwaj

Chris Willis

Lingyun Li

Fazeela Morshed

Renato Sklerj

Judith Peterschmitt

Jeremy Clinton Wilt

Friedrich Blatter

Christopher Willis

Jeffrey Skell

Robert M Wenslow Jr

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.

Inhibitors of glucosylceramide synthase

The present disclosure relates to: a) solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III); b) pharmaceutical compositions comprising one or more solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III), and optionally, a pharmaceutically acceptable carrier or diluent; c) methods of treating tumors or cancers by administering one or more solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III) to a subject in need thereof; and d) methods for the preparation of solid state forms of a compound of Formula (I), a compound of Formula (II), and a compound of Formula (III).

Solid state forms of substituted pyrazolopyrimidines and uses thereof

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described. 

Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

Glucosylceramide synthase inhibitors

Growing community of inventors

Lexington, MA, United States of America

Hanlan Liu